Freaky Friday Potpourri
News & Views across Cannaland.
Note: Cannabis Confidential shifted content strategy in 2026 with insights from trusted partners, industry insiders, and thought leaders who’ve got something to say. There will be no more paywalls or content fees; think of it as The Players Tribune for the cannabis industry, with an ethos of honesty, trust and respect.
We fired up the final frame of this five-session set to find risk assets higher as fears of disruptive AI and outsized tech spending took a breather. Bitcoin finished 11% higher to $70K, although it remains well below where it was when DJT took office.
^ noted as DJT’s youth vote was -48% per YouGov in December, the midterms are 269 days away, and cannabis is the other tentpole for the youth vote.
Our sector remains in hurry-up-and-wait mode as Pam Bondi purportedly dots the I’s and crosses her T’s, or so they say. The sooner the better, naturally, as this dust in the wind price action is both FUBAR and frustrating.
Earnings are approaching and despite Curaleaf offering a constructive forward look, we’re expecting more of the same in the status quo: muddled top-lines, optimization, efficiencies, and a look ahead to news states and fresh demand in a post-intoxicating hemp world to offset price compression and increased (same store sale) competition.
The ETF continues to base above the 200day, which is also the DJT EO gap, so we’ll be keeping an eye on that level in the absence of news, while understanding that a massive fundamental shift (S3) will trump the technicals 💯/ 💯.
MSOS ended today’s session +5% (+3% for the week; -10% YTD) as we look forward to the end of standing in a circle shooting at each other and taking a 180-degree turn to make new acquaintances, be them institutions, U.S. exchanges, or CPG M&A.
Top Stories
Why cops are backing cannabis rescheduling
Investor Outlook: Medical cannabis grows as U.S. reclassification nears
Wisconsin Democrats Renew Push To Fully Legalize Cannabis
Florida Medical Cannabis Sales Top $151 Million in January
Can Trump Marijuana Rescheduling Break Pennsylvania’s Legalization Deadlock?
Oklahoma governor wants to recriminalize $600M medical cannabis industry
Rhode Island Regulators Review Restrictions On Hemp-Derived THC Drinks
Thailand’s Cannabis Experiment Faces Moment of Truth at Polls
Over 1 in 5 Young Adults Use Cannabis or Alcohol for Sleep Aid
Industry Headlines
Ohio Attorney General Dave Yost Sues Multistate Cannabis Operators for Anti-Competitive Practices
Nick Sosiak on Cannara and the Business of Cannabis 📺
TDR: Jushi CSO Trent Woloveck 👇
“We are on the doorstep of having major federal reform and the dominoes that fall thereafter are going to be fast and furious and I don’t think that’s just 280E tax liabilities… but a whole litany of other things. PA, MA, uplisting, SAFE Banking…”
Random Thoughts
I don’t spend much time on X anymore but pals send me tidbits, such as this note (from a platform I’m unfamiliar with) that included another topic we’ve touched on that is potentially closer than most people think:
“it could include language around financial plumbing, including banking, custody, and institutional access for cannabis-related securities.”
^ we need proper plumbing prior to legitimate liquidity.
A late day call Tuesday echoed much of what was in this article: DJT’s S3 wasn’t lip service, and PB is going to follow through on S3 sooner rather than later.
Still, we believe the first domino (AG PB S3) is in the process of falling and the knock-on effect will be powerful over time and through what promises to be insane volatility.
We expect a second tranche of reform to happen prior to the midterms (or included in the final rule) although we’re well aware world events have other plans.
The Market That Matters Most: How New York’s Cannabis Market Could happen
Stems & Seeds
And ICYMI, this is pretty insane:
Andira’s Silvanex™ Shows Zero MRSA Resistance Potential in Landmark AMR Study
“MRSA remains one of the greatest challenges in AMR. To show no resistance over 20 passages is a watershed moment in infection control. Silvanex™ isn’t just a new tool — it could reset how hospitals protect their patients,” said Dr. Dana Lambert, CEO & Founder at Andira Pharmaceuticals. “This study shows that Silvanex™ could represent a durable, routine-use solution that finally breaks the cycle of resistance. That’s not incremental innovation — it’s a revolution for infection control.”
Have a safe journey, please enjoy responsibly.
If you’d like to help Mission [Green] change federal cannabis policies, please click here.
CB1 has positions in/ advises some of the companies mentioned and nothing contained herein should be considered advice.
@Todd Harrison
Will the DHS shutdown have to be averted before rescheduling is announced to fit Trump's law and order narrative?
I can't think of any other reason for a delay.